EMAIL THIS PAGE TO A FRIEND

Journal of experimental & clinical cancer research : CR

Promoter methylation of tumor suppressor genes in pre-neoplastic lesions; potential marker of disease recurrence.


PMID 25091577

Abstract

Epigenetic alterations of specific genes have been reported to be related to colorectal cancer (CRC) transformation and would also appear to be involved in the early stages of colorectal carcinogenesis. Little data are available on the role of these alterations in determining a different risk of colorectal lesion recurrence. The aim of the present study was to verify whether epigenetic alterations present in pre-neoplastic colorectal lesions detected by colonoscopy can predict disease recurrence. A retrospective series of 78 adenomas were collected and classified as low (35) or high-risk (43) for recurrence according to National Comprehensive Cancer Network guidelines. Methylation alterations were analyzed by the methylation-specific multiplex ligation probe assay (MS-MLPA) which is capable of quantifying methylation levels simultaneously in 24 different gene promoters. MS-MLPA results were confirmed by pyrosequencing and immunohistochemistry. Higher levels of methylation were associated with disease recurrence. In particular, MLH1, ATM and FHIT gene promoters were found to be significantly hypermethylated in recurring adenomas. Unconditional logistic regression analysis used to evaluate the relative risk (RR) of recurrence showed that FHIT and MLH1 were independent variables with an RR of 35.30 (95% CI 4.15-300.06, P = 0.001) and 17.68 (95% CI 1.91-163.54, P = 0.011), respectively. Histopathological classification does not permit an accurate evaluation of the risk of recurrence of colorectal lesions. Conversely, results from our methylation analysis suggest that a classification based on molecular parameters could help to define the mechanisms involved in carcinogenesis and prove an effective method for identifying patients at high risk of recurrence.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1411944
ANTI-FHIT antibody produced in mouse, clone 1A2, ascites fluid, buffered aqueous solution
SAB1411945
ANTI-FHIT antibody produced in mouse, clone 3D3, purified immunoglobulin, buffered aqueous solution
SAB1411946
ANTI-FHIT antibody produced in mouse, clone 1B5, purified immunoglobulin, buffered aqueous solution
SAB1411947
ANTI-FHIT antibody produced in mouse, clone 1C5, purified immunoglobulin, buffered aqueous solution
SAB1411948
ANTI-FHIT antibody produced in mouse, clone 3A5, purified immunoglobulin, buffered aqueous solution
SAB1412147
ANTI-FHIT antibody produced in mouse, clone 1H2, purified immunoglobulin, buffered aqueous solution
SAB1412148
ANTI-FHIT antibody produced in mouse, clone 2G3, purified immunoglobulin, buffered aqueous solution
HPA018840
Anti-FHIT antibody produced in rabbit, Ab2, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
HPA018909
Anti-FHIT antibody produced in rabbit, Ab1, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4500892
Anti-FHIT antibody produced in rabbit, affinity isolated antibody
WH0002272M1
Monoclonal Anti-FHIT antibody produced in mouse, clone 1C3, purified immunoglobulin, buffered aqueous solution
SAB1403820
Monoclonal Anti-FHIT antibody produced in mouse, clone 1E3, purified immunoglobulin, buffered aqueous solution